Cover Image
市場調查報告書

顯微多發性血管炎(MPA):開發平台分析

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 302487
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
顯微多發性血管炎(MPA):開發平台分析 Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 50 Pages
簡介

顯微多發性血管炎(MPA)目前仍是未知的疾病,是血管發炎造成的發病,並損及內臟器官。最容易受到MPA侵害的部位有腎臟和肺,神經,皮膚,關節等。主要的症狀有呼吸急促和咳嗽,發熱,食慾不振,皮疹,肌肉痛·關節痛等。此外主要治療方法有免疫抑制療法等。

本報告提供全球各國治療顯微多發性血管炎(MPA)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

顯微多發性血管炎概要

治療藥的開發

  • 顯微多發性血管炎開發中產品:概要
  • 顯微多發性血管炎開發中產品:比較分析

企業正在開發的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Aprogen, Inc.
  • ChemoCentryx, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • Teijin Pharma Limited

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • belimumab
  • CCX-168
  • immune globulin (human)
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar

最新開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8942IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 2, 3 and 2 respectively.

Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Microscopic Polyangiitis (MPA) - Overview
  • Microscopic Polyangiitis (MPA) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
    • Celltrion Inc
    • ChemoCentryx Inc
    • Coherus BioSciences Inc
    • GlaxoSmithKline Plc
    • Panacea Biotec Ltd
    • Sandoz International GmbH
    • Teijin Pharma Ltd
  • Microscopic Polyangiitis (MPA) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Microscopic Polyangiitis (MPA) - Drug Profiles
    • avacopan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Microscopic Polyangiitis (MPA) - Dormant Projects
  • Microscopic Polyangiitis (MPA) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
      • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Ltd, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2017
  • Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top